EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR

Li Luo, Denghui Wei, Yihui Pan, Qiu-Xia Wang, Jian-Xiong Feng, Bing Yu, Tiebang Kang, Junhang Luo iD, Jiefeng Yang, Song Gao iD

Cancer Communications · 2023

DOI: 10.1002/cac2.12428 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Communications, 2023. Verfasst von Li Luo und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell renal cell carcinoma (ccRCC) is the most lethal renal cancer. An overwhelming increase of patients experience tumor progression and unfavorable prognosis. However, the molecular events underlying ccRCC tumorigenesis and metastasis remain unclear. Therefore, uncovering the underlying mechanisms will pave the way for developing novel therapeutic targets for ccRCC. In this study, we sought to investigate the role of mitofusin‐2 (MFN2) in supressing ccRCC tumorigenesis and metastasis.

Methods

The expression pattern and clinical significance of MFN2 in ccRCC were analyzed by using the Cancer Genome Atlas datasets and samples from our independent ccRCC cohort. Both in vitro and in vivo experiments, including cell proliferation, xenograft mouse models and transgenic mouse model, were used to determine the role of MFN2 in regulating the malignant behaviors of ccRCC. RNA‐sequencing, mass spectrum analysis, co‐immunoprecipitation, bio‐layer interferometry and immunofluorescence were employed to elucidate the molecular mechanisms for the tumor‐supressing role of MFN2. Results we reported a tumor‐suppressing pathway in ccRCC, characterized by mitochondria‐dependent inactivation of epidermal growth factor receptor (EGFR) signaling. This process was mediated by the outer mitochondrial membrane (OMM) protein MFN2. MFN2 was down‐regulated in ccRCC and associated with favorable prognosis of ccRCC patients. in vivo and in vitro assays demonstrated that MFN2 inhibited ccRCC tumor growth and metastasis by suppressing the EGFR signaling pathway. In a kidney‐specific knockout mouse model, loss of MFN2 led to EGFR pathway activation and malignant lesions in kidney. Mechanistically, MFN2 preferably binded small GTPase Rab21 in its GTP‐loading form, which was colocalized with endocytosed EGFR in ccRCC cells. Through this EGFR‐Rab21‐MFN2 interaction, endocytosed EGFR was docked to mitochondria and subsequently dephosphorylated by the OMM‐residing tyrosine‐protein phosphatase receptor type J (PTPRJ).

Conclusions

Our findings uncover an important non‐canonical mitochondria‐dependent pathway regulating EGFR signaling by the Rab21‐MFN2‐PTPRJ axis, which contributes to the development of novel therapeutic strategies for ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAnimalsHumansMiceCarcinogenesisCell Line, TumorErbB ReceptorsGTP PhosphohydrolasesMitochondriaMitochondrial Proteins

Stichwörter der Autor:innen

EGFR signaling pathwayMFN2PTPRJRab21ccRCC

Substanzen

EGFR protein, humanErbB ReceptorsGTP PhosphohydrolasesMFN2 protein, humanMitochondrial ProteinsMfn2 protein, mouse

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
  • Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, P. R. China.
  • Department of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Junhang Luo, Song Gao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province

Zitieren

APA

Luo, L., Wei, D., Pan, Y., Wang, Q. X., Feng, J. X., Yu, B., Kang, T., Luo, J., Yang, J., & Gao, S. (2023). MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR. Cancer Communications. https://doi.org/10.1002/cac2.12428

Vancouver

Luo L, Wei D, Pan Y, Wang QX, Feng JX, Yu B, et al. MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR. Cancer Communications. 2023. doi:10.1002/cac2.12428

BibTeX
@article{Luo2023,
  author = {Luo, Li and Wei, Denghui and Pan, Yihui and Wang, Qiu-Xia and Feng, Jian-Xiong and Yu, Bing and Kang, Tiebang and Luo, Junhang and Yang, Jiefeng and Gao, Song},
  title = {MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria‐dependent dephosphorylation of EGFR},
  journal = {Cancer Communications},
  year = {2023},
  doi = {10.1002/cac2.12428}
}
Kostenlos starten →